Global Information
회사소개 | 문의

정맥혈전색전증(VTE) : 주요 24개 시장 예측

Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 08월 상품 코드 667520
페이지 정보 영문 78 Pages
가격
US $ 5,800 ₩ 6,658,400 PDF by E-mail (Single User License)
US $ 8,700 ₩ 9,987,600 PDF by E-mail (Site License)
US $ 10,400 ₩ 11,939,200 PDF by E-mail (Global License)


정맥혈전색전증(VTE) : 주요 24개 시장 예측 Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018-2028
발행일: 2018년 08월 페이지 정보 : 영문 78 Pages

한글목차

세계 주요 24개국의 정맥혈전색전증(VTE : Venous Thromboembolism) 이환 상황에 대해 조사했으며, 유병자수 추정과 예측, 국가·연령층·성별·질환 구분별 내역, 질환 개요, 위험인자, 질환 진단과 예후, 주요 증상과 병존증 등의 정보를 전해드립니다.

조사 대상 국가

  • 미국
  • 캐나다
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 영국
  • 폴란드
  • 노르웨이
  • 스웨덴
  • 덴마크
  • 핀란드
  • 오스트리아
  • 포르투갈
  • 그리스
  • 터키
  • 일본
  • 중국
  • 한국
  • 인도
  • 호주
  • 브라질
  • 멕시코
  • 아르헨티나

목차

  • 도표
  • 서론
  • 병인
  • 위험인자와 예방
  • 질환 진단
  • 변이 : 지역/민족별
  • 질환 예후와 임상 경과
  • 질환과 관련된 주요 합병증/특징
  • 환자수를 정량화하는 방법
  • 정맥혈전색전증(VTE)의 최대 유병자수
  • 심부정맥혈전증(DVT)
  • 폐색전증(PE)
  • 정맥혈전색전증(VTE) 환자의 병존 질환
  • 약어
  • 기타 서비스 및 솔루션
  • 보고서 및 발행물
  • 온라인 역학 데이터베이스
  • 온라인 약가 데이터베이스
  • 참고 문헌
  • 부록
KSM 18.08.03

영문목차

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Venous Thromboembolism in 24 Major Markets

Venous thromboembolism (VTE) is a disease in which thrombi or blood clots form in venous blood vessels and either remain at their site of origin or move with the blood flow until they reach a vessel with a diameter small enough to form an occlusion. Clots formed in the large limb or pelvic veins cause a clinical manifestation of VTE called deep vein thrombosis (DVT), while emboli (detached clot fragments) which move to and cause obstruction of pulmonary blood vessels cause a pulmonary embolism (PE). VTE is the third most common cardiovascular disease worldwide (after myocardial infarction and ischaemic stroke), with 2-5% of the global population affected throughout their lives.

This report provides the current prevalent population for VTE across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Norway, Sweden, Denmark, Finland, Austria, Portugal, Greece, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, DVT and PE patient subsets, as well as those with the main co-morbidities, have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for VTE include:

  • Cancer
  • Inflammatory bowel disease
  • Obesity
  • Cardiovascular diseases

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global VTE market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of VTE and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding on the impact of specific co-morbid conditions on the prevalent population of VTE patients.
  • Identification of VTE patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of VTE patients.

Table of Contents

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR VENOUS THROMBOEMBOLISM
  • DEEP VEIN THROMBOSIS
  • PULMONARY EMBOLISM
  • COMORBIDITIES OF VENOUS THROMBOEMBOLISM PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. VTE risk factors
  • Table 2. Prevalence of VTE, total (000s)
  • Table 3. Prevalence of VTE, males (000s)
  • Table 4. Prevalence of VTE, females (000s)
  • Table 5. Prevalence of DVT, total (000s)
  • Table 6. Prevalence of DVT, males (000s)
  • Table 7. Prevalence of DVT, females (000s)
  • Table 8. Prevalence of PE, total (000s)
  • Table 9. Prevalence of PE, males (000s)
  • Table 10. Prevalence of PE, females (000s)
  • Table 11. VTE patients with post-thrombotic syndrome, total (000s)
  • Table 12. VTE patients with venous ulcers, total (000s)
  • Table 13. VTE patients with major bleeding from prophylaxis, total (000s)
  • Table 14. PE patients with chronic thromboembolic pulmonary hypertension, total (000s)
  • Table 15. Abbreviations and acronyms used in the report
  • Table 16. USA prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 17. USA prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 18. Canada prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 19. Canada prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 20. France prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 21. France prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 22. Germany prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 23. Germany prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 24. Italy prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 25. Italy prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 26. Spain prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 27. Spain prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 28. UK prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 29. UK prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 30. Poland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 31. Poland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 32. Norway prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 33. Norway prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 34. Sweden prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 35. Sweden prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 36. Denmark prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 37. Denmark prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 38. Finland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 39. Finland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 40. Austria prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 41. Austria prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 42. Portugal prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 43. Portugal prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 44. Greece prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 45. Greece prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 46. Turkey prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 47. Turkey prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 48. Japan prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 49. Japan prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 50. China prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 51. China prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 52. South Korea prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 53. South Korea prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 54. India prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 55. India prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 56. Australia prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 57. Australia prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 58. Brazil prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 59. Brazil prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 60. Mexico prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 61. Mexico prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 62. Argentina prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 63. Argentina prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research